YOKNEAM, Israel, May 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Jefferies Healthcare Conference in New York on June 5, 2024.
The fireside chat, moderated by Matt Taylor, Managing Director, Senior Healthcare Analyst, is scheduled for 7:30 am Eastern Time on Wednesday, June 5 and a live webcast of the presentation can be accessed here. InMode will also hold one-on-one investor meetings in person that same day. To schedule a meeting, please contact your Jefferies representative.
For more information about the event, visit InMode's investor relations site here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
Last Trade: | US$17.19 |
Daily Change: | 0.04 0.23 |
Daily Volume: | 859,892 |
Market Cap: | US$1.310B |
September 04, 2024 August 06, 2024 July 31, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB